|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
Q2 FY2021
As of Jun 30, 2021
|
Q1 FY2021
As of Mar 31, 2021
|
Q4 FY2020
As of Dec 31, 2020
|
Q3 FY2020
As of Sep 30, 2020
|
Q2 FY2020
As of Jun 30, 2020
|
Q1 FY2020
As of Mar 31, 2020
|
Q4 FY2019
As of Dec 31, 2019
|
Q3 FY2019
As of Sep 30, 2019
|
Q2 FY2019
As of Jun 30, 2019
|
Q1 FY2019
As of Mar 31, 2019
|
Q4 FY2018
As of Dec 31, 2018
|
Q3 FY2018
As of Sep 30, 2018
|
Q2 FY2018
As of Jun 30, 2018
|
Q1 FY2018
As of Mar 31, 2018
|
Q3 FY2017
As of Oct 31, 2017
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||||||||
| Current assets | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Marketable securities | ||||||||||||||||||||
| Accounts receivable | ||||||||||||||||||||
| Unbilled receivable | ||||||||||||||||||||
| Prepaid and other current assets | ||||||||||||||||||||
| Total current assets | ||||||||||||||||||||
| Marketable Securities | ||||||||||||||||||||
| Other assets | ||||||||||||||||||||
| Property and equipment, net | ||||||||||||||||||||
| Right of use assets - operating leases | ||||||||||||||||||||
| Patents and patent applications, net | ||||||||||||||||||||
| Other non-current assets | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| Liabilities and Stockholders' Equity | ||||||||||||||||||||
| Liabilities | ||||||||||||||||||||
| Current liabilities | ||||||||||||||||||||
| Accounts payable and accrued liabilities | ||||||||||||||||||||
| License fees payable | ||||||||||||||||||||
| Accrued salaries and wages | ||||||||||||||||||||
| Royalty payable | ||||||||||||||||||||
| Deferred revenue | ||||||||||||||||||||
| Operating leases - current | ||||||||||||||||||||
| Convertible debt - current | ||||||||||||||||||||
| Total current liabilities | ||||||||||||||||||||
| Long-term liabilities | ||||||||||||||||||||
| Operating leases - long term | ||||||||||||||||||||
| Total long-term liabilities | ||||||||||||||||||||
| Convertible debt, net of unamortized discount | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| Stockholders' equity | ||||||||||||||||||||
| Common stock; par value $0.001; 200,000,000 shares authorized; 5,164,951 and 4,909,846 shares issued and outstanding at September 30, 2022 and December 31, 2021, respectively | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Accumulated other comprehensive loss | ||||||||||||||||||||
| Accumulated deficit | ||||||||||||||||||||
| Total stockholders' equity | ||||||||||||||||||||
| Total liabilities and stockholders' equity | ||||||||||||||||||||
Loading...
